ID: ALA3134134

Max Phase: Preclinical

Molecular Formula: C22H35N3

Molecular Weight: 341.54

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  c1cc(N2CCC(N3CCCC3)CC2)ccc1CCCN1CCCC1

Standard InChI:  InChI=1S/C22H35N3/c1-2-14-23(13-1)15-5-6-20-7-9-21(10-8-20)25-18-11-22(12-19-25)24-16-3-4-17-24/h7-10,22H,1-6,11-19H2

Standard InChI Key:  FWDODVLDFMFFSW-UHFFFAOYSA-N

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 341.54Molecular Weight (Monoisotopic): 341.2831AlogP: 3.78#Rotatable Bonds: 6
Polar Surface Area: 9.72Molecular Species: BASEHBA: 3HBD: 0
#RO5 Violations: 0HBA (Lipinski): 3HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 10.34CX LogP: 3.59CX LogD: -1.57
Aromatic Rings: 1Heavy Atoms: 25QED Weighted: 0.78Np Likeness Score: -1.15

References

1. Camerino MA, Zhong N, Dong A, Dickson BM, James LI, Baughman BM, Norris JL, Kireev DB, Janzen WP, Arrowsmith CH, Frye SV..  (2013)  The structure-activity relationships of L3MBTL3 inhibitors: flexibility of the dimer interface.,  (11): [PMID:24466405] [10.1039/c3md00197k]

Source